Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$105.55 USD
-0.84 (-0.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $105.45 -0.10 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 61 - 80 ( 512 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ESMO 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 22.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended July 28.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Optimistic on Ayvakit?s Future Growth in ISM, Despite Investor Hesitation; Reit. Buy and $85 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended July 7
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 23.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
EHA 2023 Roundup for Covered Companies (Part 1)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Blueprint Showcases Promising Early-Stage EGFRs and CDK2 Assets During ASCO ?23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Initial Takeaways for Day 5 of ASCO 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D